145 related articles for article (PubMed ID: 11375761)
1. Candida proteases and their inhibition: prospects for antifungal therapy.
Stewart K; Abad-Zapatero C
Curr Med Chem; 2001 Jul; 8(8):941-8. PubMed ID: 11375761
[TBL] [Abstract][Full Text] [Related]
2. The secreted aspartic proteinases as a new target in the therapy of candidiasis.
Bein M; Schaller M; Korting HC
Curr Drug Targets; 2002 Oct; 3(5):351-7. PubMed ID: 12182226
[TBL] [Abstract][Full Text] [Related]
3. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
Calugi C; Guarna A; Trabocchi A
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
[TBL] [Abstract][Full Text] [Related]
4. Novel non-peptidic small molecule inhibitors of secreted aspartic protease 2 (SAP2) for the treatment of resistant fungal infections.
Dong G; Liu Y; Wu Y; Tu J; Chen S; Liu N; Sheng C
Chem Commun (Camb); 2018 Dec; 54(96):13535-13538. PubMed ID: 30431632
[TBL] [Abstract][Full Text] [Related]
5. The crystal structure of protease Sapp1p from Candida parapsilosis in complex with the HIV protease inhibitor ritonavir.
Dostál J; Brynda J; Hrušková-Heidingsfeldová O; Pachl P; Pichová I; Rezáčová P
J Enzyme Inhib Med Chem; 2012 Feb; 27(1):160-5. PubMed ID: 22146051
[TBL] [Abstract][Full Text] [Related]
6. Anti-fungal therapy at the HAART of viral therapy.
Munro CA; Hube B
Trends Microbiol; 2002 Apr; 10(4):173-7. PubMed ID: 11912023
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of aspartic proteases in human diseases: molecular modeling comes of age.
Hoegl L; Korting HC; Klebe G
Pharmazie; 1999 May; 54(5):319-29. PubMed ID: 10368824
[TBL] [Abstract][Full Text] [Related]
8. Structural determinants for subnanomolar inhibition of the secreted aspartic protease Sapp1p from
Dostál J; Brynda J; Vaňková L; Zia SR; Pichová I; Heidingsfeld O; Lepšík M
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):914-921. PubMed ID: 33843395
[TBL] [Abstract][Full Text] [Related]
9. Structure of secreted aspartic proteinases from Candida. Implications for the design of antifungal agents.
Abad-Zapatero C; Goldman R; Muchmore SW; Hutchins C; Oie T; Stewart K; Cutfield SM; Cutfield JF; Foundling SI; Ray TL
Adv Exp Med Biol; 1998; 436():297-313. PubMed ID: 9561233
[TBL] [Abstract][Full Text] [Related]
10. Aspartic proteases in drug discovery.
Eder J; Hommel U; Cumin F; Martoglio B; Gerhartz B
Curr Pharm Des; 2007; 13(3):271-85. PubMed ID: 17313361
[TBL] [Abstract][Full Text] [Related]
11. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors.
Cutfield SM; Dodson EJ; Anderson BF; Moody PC; Marshall CJ; Sullivan PA; Cutfield JF
Structure; 1995 Nov; 3(11):1261-71. PubMed ID: 8591036
[TBL] [Abstract][Full Text] [Related]
12. Targeting fungal virulence factor by small molecules: Structure-based discovery of novel secreted aspartic protease 2 (SAP2) inhibitors.
Li C; Liu Y; Wu S; Han G; Tu J; Dong G; Liu N; Sheng C
Eur J Med Chem; 2020 Sep; 201():112515. PubMed ID: 32623209
[TBL] [Abstract][Full Text] [Related]
13. HIV proteinase inhibitors: do they really work against Candida in a clinical setting?
Cassone A; Cauda R
Trends Microbiol; 2002 Apr; 10(4):177-8. PubMed ID: 11912024
[No Abstract] [Full Text] [Related]
14. The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors.
Monod M; Borg-von Zepelin M; Telenti A; Sanglard D
Dermatology; 1999; 198(4):412-4. PubMed ID: 10490300
[No Abstract] [Full Text] [Related]
15. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.
Cassone A; De Bernardis F; Torosantucci A; Tacconelli E; Tumbarello M; Cauda R
J Infect Dis; 1999 Aug; 180(2):448-53. PubMed ID: 10395861
[TBL] [Abstract][Full Text] [Related]
16. Contribution of Aspartic Proteases in Candida Virulence. Protease Inhibitors against Candida Infections.
Monika S; Małgorzata B; Zbigniew O
Curr Protein Pept Sci; 2017; 18(10):1050-1062. PubMed ID: 27514853
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
Kuhnert M; Steuber H; Diederich WE
J Med Chem; 2014 Jul; 57(14):6266-72. PubMed ID: 25006983
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro.
Gruber A; Speth C; Lukasser-Vogl E; Zangerle R; Borg-von Zepelin M; Dierich MP; Würzner R
Immunopharmacology; 1999 Apr; 41(3):227-34. PubMed ID: 10428651
[TBL] [Abstract][Full Text] [Related]
19. Biosensor-based screening and characterization of HIV-1 inhibitor interactions with Sap 1, Sap 2, and Sap 3 from Candida albicans.
Backman D; Monod M; Danielson UH
J Biomol Screen; 2006 Mar; 11(2):165-75. PubMed ID: 16418316
[TBL] [Abstract][Full Text] [Related]
20. Secreted aspartic proteases as virulence factors of Candida species.
Monod M; Borg-von ZM
Biol Chem; 2002; 383(7-8):1087-93. PubMed ID: 12437091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
